Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), JCI Insight, 7

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.

McAuliffe J. et al, (2021), J Immunother Cancer, 9

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.

Datoo MS. et al, (2021), Lancet, 397, 1809 - 1818

Efficacy of a low dose candidate malaria vaccine, R21 in adjuvant Matrix-M™, with seasonal administration to children in Burkina Faso

EWER K. et al, (2021), The Lancet

Viral vectored vaccines for prostate cancer.

Hill AVS. et al, (2021), CANCER IMMUNOLOGY RESEARCH, 9

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer

Tuthill M. et al, (2020), ANNALS OF ONCOLOGY, 31, S543 - S543

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

HODGSON S., (2020), The Lancet

Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.

Tuthill M. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38

Include forthcoming?